BCLI:NSD-Brainstorm Cell Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.99

Change

0.00 (0.00)%

Market Cap

USD 0.16B

Volume

2.04M

Average Target Price

USD 20.00 (+300.80%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in Phase II for the treatment of multiple sclerosis, and preclinical trial for Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company has a partnership with Catalent for the manufacture of NurOwn, an autologous cellular therapy. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD56.71B 21.08 16.42
REGN Regeneron Pharmaceuticals, Inc

N/A

USD54.24B 20.76 16.02
MRNA Moderna, Inc

N/A

USD43.20B N/A N/A
SGEN Seagen Inc

N/A

USD29.62B 65.69 65.81
ALXN Alexion Pharmaceuticals, Inc

N/A

USD26.98B 28.36 26.40
RPRX Royalty Pharma plc

N/A

USD25.62B 22.60 9.61
BGNE BeiGene, Ltd

N/A

USD25.22B N/A N/A
BNTX BioNTech SE

N/A

USD24.53B -99,999.99 N/A
GMAB Genmab A/S

N/A

USD23.24B 26.59 2.65
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing BCLI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.59% 59% F 66% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.59% 59% F 66% D
Trailing 12 Months  
Capital Gain 26.33% 55% F 69% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.33% 55% F 69% D+
Trailing 5 Years  
Capital Gain 81.45% 80% B- 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 81.45% 80% B- 72% C-
Average Annual (5 Year Horizon)  
Capital Gain 37.01% N/A N/A 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 37.01% N/A N/A 87% B+
Risk Return Profile  
Volatility (Standard Deviation) 64.57% N/A N/A 16% F
Risk Adjusted Return 57.31% N/A N/A 76% C
Market Capitalization 0.16B 36% F 34% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 5.18 39% F 26% F
Price / Cash Flow Ratio -14.01 72% C- 83% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -288.40% 8% F 2% F
Return on Invested Capital 638.30% 99% A+ 100% A+
Return on Assets -85.98% 5% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 6.78 38% F 23% F
Short Percent 24.03% 7% F 8% F
Beta 0.90 76% C 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector